Citi analyst Joanne Wuensch lowered the firm’s price target on Nevro (NVRO) to $5 from $6 and keeps a Neutral rating on the shares as part of a 2025 outlook for the U.S. medical technology sector. The stocks that outperformed in 2024 followed the traditional med tech path, and Citi expects the same in 2025: launching differentiated products that can be leveraged to the bottom-line, with management teams providing consistent delivery, the analyst tells investors in a research note. Citi names Boston Scientific (BSX) and Insulet (PODD) its top picks for 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO:
- Nevro price target lowered to $4 from $7 at Canaccord
- Nevro resumed with an Equal Weight at Wells Fargo
- Nevro downgraded to Underweight from Equal Weight at Morgan Stanley
- Nevro announces publication of new data on Nevro1 SI Joint Fusion System
- Nevro Corp. Reports Strong Q3 2024 Financial Performance
Questions or Comments about the article? Write to editor@tipranks.com